Symmetra Biosciences Inc. specializes in helping global life sciences CDMO, and specialty chemicals companies in the implementation of sound business strategies. We work "together" to develop innovative practical solutions on issues ranging from business and technology development, outsourcing/sourcing, CDMO relationships (Alliance Management). Symmetra also provides M&A advisory to P.E. firms, interim CEO and non-executive board services to private-equity sponsored companies.

Callery LLC, is a global leader in the development and manufacturing of speciality alkholates, diborane and borane reagents used in lifesciences (pharma & agro) and sermiconductor applications. Callery was owned by PE firm Edgewaters Capital Partners, and was a carve-out from BASF. Reporting to the Board of Directors of Callery LLC. Full P&L responsibility. Responsible for strategy, product portfolio development including business expansion. Developed and implemented strategic plans to achieve 2x EBITDA growth in 3 years. Led the sale of Callery LLC to Ascensus Specialties (a Windpoint Capital Partners company) - a global leader in Sodium Borohydride production

Alcami was an end-to-end CDMO of small molecules. Business leader for Alcami Drug Suubstance activities - responsible for developing and implementation of Alcami business Strategy and global expansion, P&L responsibility. Developing best-in-class commercial API strategy, bringing a wealth of knowledge and customer network in the pharma innovators and generics APIs.

Accountability for leading business development projects from search and analysis through negotiation and closure. Leading cross-functional teams in strategy development - scouting, scientific and product licensing, and commercial transactions. Experience in commercial development of drug-substances/ APIs (small molecules, biochemicals, microbial and mammalian) for custom development & manufacturing (CDMO) and generics.

Lonza is the global leader in the production and support of active chemical and biotechnological pharmaceutical ingredients to the pharmaceutical, healthcare and life science industries. Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss ExchangeDeveloped and implemented strategic plans to establish Lonza's presence in India in a challenging business environment. Complete P&L and people management responsibilities - building and managing a 100 member team. Organization Development - Implemented systems and processes to create a "empowering team" environment.Project Lead of M&A team which is involved in active negotiations to form a majority owned joint venture in India in the area of CDMO and APIs for innovators/generic Pharma. Led M&A team in the acquisition of Symbiosis, Bangalore in 2009 - New CRO business in the area of Bio-sciences. Negotiated with AP Govt. (APIIC) to acquire 25 acres of land in Biotech Park "Genome Valley" Hyderabad to establish 80,000 sq. ft. of Lonza R&D center for Bio-sciences,Cell-Therapy and Biosimilars development and scale-up.Leading the expansion of small molecules (advanced intermediates and APIs) business in India - sales growth in India from $1.5 M (2004) to $100 M (2012)

As Vice-President of Contract Manufacturing in Lonza's Exclusive Synthesis Business Unit (LCM), I headed business activities in late in life cycle management of selected innovator's APIs leading to Generics. Develop and presented business plans which were approved by the Lonza Executive Committee, established channel partners s. Established strategic relationships with key customers in Asia, North America and Israel to promote a new generic busines. Set up Generic business team and participated in the development of product portfolio to grow Lonza generic business across chemical and biologic platforms. Teams' short term focus was to penetrate generic markets with the sales of Lonza commercial products licensed from innovators. Developed new API's for Generic customers in the area of schedule B controlled substances,Member of the core-team for biosimilar strategy development- researching/evaluating/developing Lonza strategy for biosimilar and developing strategic alliances - Licensing of Lipoxen technology from Serum Institute.

Borregaard Synthesis is the fine chemical division of Borregaard industries of Sarpsborg, Norway. The company develops, contract manufactures and markets complex organic small molecules for pharmaceutical, health-imaging, and microelectronics industries.Spearheaded the new strategic sourcing group tasked with building a 'network' of companies in India with a good track record and strong emphasis on preserving the intellectual property of Borregaard, and its customers. This group's activities offered sourcing solutions to internal manufacturing, as well as to our pharmaceuticals and medical imaging customers. In all cases, Borregaard was responsible for quality assurance and logistics to guarantee the security and quality of materials to its customers in US and EU.Negotiated equity investments in a partner company in India - Suven Life-SciencesMember Board of Directors of Suven Lifesciences, India.

Led the merger negotiations of Polyorganix Inc. with Borregaard Industries. Led the integration - managing transition teams in the development of internal system requirements (ERP, SAP) for reporting to the parent company in Norway. Improved organizational effectiveness through special attention to cultural diversity, employee empowerment and cross-functional project teams. Championed the idea of global steering committees for project evaluation based on core competence of each site, and integrating development and manufacturing at these sites.Directed technology development efforts to create a portfolio of products for life sciences and micro-electronic applications. Successfully implemented the imidazole-based ionic liquid product line for metal catalyzed chiral synthesis and CASE applications.

a privately held Massachusetts corporation owned by PE firm Affiliated Technology Group. This was a greenfield start-up CDMO business specializing in advanced pharmaceuticals intermediates, and products specializing into photo imaging and microelectronics applications.Responsible for directing the R & D team / organization in developing processes technologies appropriate for larger scale synthesis and ultimately commercial manufacturing of intermediates for pharma NCE's and medical imaging applications.